SCHEMBL1789608

SCHEMBL1789608

Cc1cc(CNC(=O)c2ccc3c(c2)CCN(C2=CC=C2)CC3)no1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.49
ROCK2 O75116 2/20 0.46
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
EPHX2 P34913 1/20 0.38
HDAC6 Q9UBN7 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
PDE10A Q9Y233 1/20 0.36
KMT2A Q03164 1/20 0.36
TAS2R8 Q9NYW2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1792607 0.83 ROCK2 (0.48) ROCK2NPC1RAB9ALMNAKMT2A
SCHEMBL1791103 0.83 LMNA (0.46) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL1792348 0.82 CYP1A2 (0.51) NPC1RAB9ALMNACYP1A2CYP2D6
SCHEMBL1787618 0.82 ROCK2 (0.46) ROCK2NPC1RAB9AHDAC6KMT2A
SCHEMBL1787686 0.82 NAMPT (0.49) NAMPTROCK2LMNAHDAC6PDE10A
SCHEMBL1787084 0.81 HPGDS (0.43) NAMPTROCK2NPC1RAB9AHDAC6
SCHEMBL1788120 0.81 HDAC6 (0.37) NPC1RAB9AHDAC6PDE10AKMT2A
SCHEMBL1790046 0.81 KDM4E (0.52) NAMPTROCK2NPC1RAB9ALMNA
SCHEMBL1787706 0.81 HDAC6 (0.43) NAMPTNPC1RAB9AHDAC6KMT2A
SCHEMBL1787825 0.80 MAPT (0.39) LMNAHDAC6KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 NAMPT 4540/4885ROCK2 2377/4885NPC1 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.